Preparation of peptide-loaded dendritic cells for cancer immunotherapy

Applied Biochemistry and Biotechnology - Part B Molecular Biotechnology

Volumn 25, Issue 1, 2003, Pages 95-99

  Morse, Michael A ^a   Clay, Tim ^a   Colling, Kirsten ^a   Lyerly, H Kim ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Cancer; Dendritic cells; Immunotherapy

Indexed keywords

CD14 ANTIGEN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 4; VACCINE;

ANTIGEN SPECIFICITY; ARTICLE; BLOOD CELL; CANCER IMMUNOTHERAPY; CELL ADHESION; CELL MATURATION; DENDRITIC CELL; HUMAN; HUMAN CELL; MONOCYTE; STEM CELL; TUMOR IMMUNITY;

CANCER VACCINES; CARCINOEMBRYONIC ANTIGEN; CARRIER PROTEINS; CD40 LIGAND; CELL DIFFERENTIATION; DENDRITIC CELLS; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HLA-A1 ANTIGEN; HUMANS; IMMUNOTHERAPY; IMMUNOTHERAPY, ACTIVE; INTERFERON TYPE II; LEUKAPHERESIS; LEUKOCYTES, MONONUCLEAR; NEOPLASMS; PEPTIDES; TNF RECEPTOR-ASSOCIATED FACTOR 3; TUMOR NECROSIS FACTOR RECEPTOR-ASSOCIATED PEPTIDES AND PROTEINS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0042413569     PISSN: 10736085     EISSN: None     Source Type: Journal    
DOI: 10.1385/MB:25:1:95     Document Type: Article

References (13)

1. Murphy, G., Tjoa, B., Ragde, H, et al. (1996) Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen. The Prostate 29, 371-380.
2. Nestle, F. O., Alijagic, S., Gilliet, M., et al. (1998) Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nature Med. 4, 328-332.
3. Morse MA, Deng Y, Hull S, Coleman D, et al. (1999) A phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcino-embryonic antigen. Clin. Cancer Res. 5, 1331-1338.
4. Suss, G. and Shortman, K. (1996) A subclass of dendritic cells kills CD4 T cells via Fas/Fas-ligand-induced apoptosis. J. Exp. Med. 183, 1789-1796.
5. Szabolcs, P., Moore, M.A.S. and Young, J.W. (1995) Expansion of immunostimulatory dendritic cells among the myeloid progeny of human CD34+ bone marrow precursors cultured with c-kit ligand, granulocyte-macrophage colony-stimulating factor, and TNF-γ. J. Immunol. 154, 5851-5861.
6. Romani, N., Reider, D., Heuer, M., et al. (1996) Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability. J. Immunol. Methods 196, 137-151.
7. Romani, N., Gruner, S., Brang, D., et al. (1994) Proliferating dendritic cell progenitors in human blood. J. Exp. Med. 180, 83-93.
8. Bender, A., Sapp, M., Schuler, G., et al. (1996) Improved methods for the generation of dendritic cells from nonproliferating progenitors in human blood. J. Immunol. Methods 196, 121-35.
9. Morse, M.A., Zhou, L.-J., Tedder, T.F., et al. (1997) Generation of dendritic cells in vitro from peripheral blood mononuclear cells with GM-CSF, IL-4, and TNF-α for use in cancer immunotherapy. Ann. Surg. 226, 6-16.
10. Markowicz, S. and Engleman, E.C. (1990) Granulocyte-macrophage colony-stimulating factor promotes differentiation and survival of human peripheral blood dendritic cells in vitro. J. Clin. Invest. 85, 955-61.
11. Ruppert, J., Friedrichs, D., Xu, H., Peters, J.H. (1991) IL-4 decreases the expression of the monocyte differentiation marker CD14, paralleled by an increasing accessory potency. Immunobiol. 182, 449-464.
12. Wong, C., Morse, M., and Nair, S.K. (1998) Induction of primary, human antigen-specific cytotoxic T lymphocytes in vitro using dendritic cells pulsed with peptides. J. Immunother. 21, 32-40.
13. Alters, S.E., Gadea, J.R., Sorich, M., et al. (1998) Dendritic cells pulsed with CEA peptide induce CEA specific CTL with restricted TCR repertoire. J. Immunother. 21, 17-26.